Chronic inflammatory demyelinating polyradiculoneuropathy
MONDO:0006702A rare neurological disorder in which there is inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) over the nerves. This affects how fast the nerve signals are transmitted and leads to loss of nerve fibers. This causes weakness, paralysis and/or impairment in motor function, especially of the arms and legs (limbs). Sensory disturbance may also be present. The motor and sensory impairments usually affect both sides of the body (symmetrical), and the degree of severity and the course of disease may vary from case to case. Some affected individuals may follow a slow steady pattern of symptoms while others may have symptoms that stabilize and then relapse.
Also known as: CIDP, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, chronic relapsing polyneuropathy, chronic inflammatory demyelinating polyneuritis
69 clinical trials for this condition and its sub-types, 62 tagged with Chronic inflammatory demyelinating polyradiculoneuropathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Chronic inflammatory demyelinating polyradiculoneuropathy
-
Lewis-Sumner syndrome 0 trials
-
New immune globulin drug shows promise for rare nerve diseases in japan
Disease control CompletedThis completed Phase 3 study tested TAK-771, a combination of immune globulin and hyaluronidase, in 26 Japanese adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN). The main goals were to check for side effects and see…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New shot could replace IV drips for nerve disease patients
Disease control CompletedThis study tested whether adults with CIDP, a nerve disorder causing weakness and numbness, could safely switch from regular intravenous immunoglobulin (IVIg) infusions to a new injectable drug called efgartigimod PH20 SC. Twenty-three participants who were stable on IVIg were gi…
Phase 4 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug KINE-101 tested for Tough-to-Treat nerve disorder
Disease control CompletedThis early-stage trial tested a single dose of a new drug called KINE-101 in 9 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hadn't improved with steroids. The main goal was to check if the drug is safe and tolerable. Researchers also looked at whether…
Phase 1 • Sponsor: Kine Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New CIDP drug shows promise in early trial
Disease control CompletedThis phase 2 study tested a drug called SAR445088 in 98 adults with CIDP, a nerve disorder causing weakness and numbness. The trial looked at how well the drug works in people who are on standard treatment, those who don't respond to it, and those who haven't tried it yet. Resear…
Phase 2 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Ultrasound probes nerve stiffness in rare nerve diseases
Knowledge-focused CompletedResearchers at Nantes University Hospital are studying whether nerves feel stiffer in people with three rare peripheral neuropathies: CIDP, CMT1a, and anti-MAG neuropathy. They use ultrasound shear wave elastography to measure nerve stiffness in 36 participants aged 18 to 65 and …
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Blood test may Fine-Tune IVIg dosing for rare nerve disorders
Knowledge-focused CompletedThis study looked at 20 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were starting intravenous immunoglobulin (IVIg) treatment. Researchers measured changes in IgG levels in the blood after the first dose to…
Sponsor: Walton Centre NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Obesity may affect immune drug dosing – study seeks answers
Knowledge-focused CompletedThis study investigates how obesity affects the way the body processes intravenous immune globulin (IVIG), a treatment for immune deficiencies. Researchers measured body composition and blood levels of IVIG in 40 obese and normal-weight patients to find the best dosing strategy. …
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Tiny study aims to unlock how blood filtering helps CIDP
Knowledge-focused CompletedThis study looked at two types of plasmapheresis (blood filtering) in 8 people with CIDP, a rare nerve disorder causing weakness. The goal was to see how each method affects immune cells in the blood. It is a very early, small study focused on understanding how these treatments w…
Early phase 1 • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Walking study reveals balance differences in nerve diseases
Knowledge-focused CompletedThis study looked at how two types of nerve diseases—inherited and acquired—affect walking and balance. Researchers used motion analysis and simple tests like the Timed Up and Go test in 67 participants. The goal was to find clear differences that could help doctors tell the two …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC